April 2010 PMID 20456731

Proton pump inhibitors: predisposers to Alzheimer disease?

M K Fallahzadeh, A Borhani Haghighi, M R Namazi

Download social card

Mentions

Peak: 2 in Jun 2021

across 4 sources since Jun 2021

Extended reach

13,217

potential audience

Total likes

166

Video views

4,886

Mentions per month

Jun 2021 – Aug 2024

Where it's discussed

Facebook6 posts
X / Twitter2 posts
YouTube2 videos
News2 articles

AI synopsis

What people are saying

The discussions include phrases like 'potential risk,' 'should be taken seriously,' and references to the need for further research, which indicate concern and interest. Users are actively engaging by questioning the long-term effects and sharing personal perspectives, though some comments remain cautious and speculative, reflecting a moderate but attentive engagement and concern for possible health impacts.

AgreementModerate agreement

Most discussions express concern or caution regarding the potential link between PPIs and Alzheimer’s, showing some support for the publication’s findings.

InterestModerate interest

Participants demonstrate moderate curiosity, engaging with the implications but not delving deeply into technical details initially.

EngagementHigh engagement

There is a high level of active discussion, with users responding, questioning, and sharing opinions about the research's significance.

ImpactModerate impact

The discussions suggest awareness of possible health implications, indicating a moderate perceived impact on medical practices and patient safety.

Abstract in brief

Proton pump inhibitors (PPIs) can interfere with the acidification of lysosomes in microglia, the brain's immune cells, which are responsible for clearing amyloid-beta (Aβ) peptides associated with Alzheimer’s disease (AD).
Since lysosomes in AD patients are less acidic, inhibiting VATPases with PPIs may further impair the breakdown of fibrillar Aβ, potentially promoting the accumulation of toxic peptides in the brain.
Long-term use of PPIs, common in treating conditions like gastroesophageal reflux disease, may pose a risk for developing AD by reducing microglial ability to clear Aβ due to increased lysosomal alkalinity.]

Read the full abstract

All mentions

Proton Pump Inhibitors and Dementia Risk Insights from ARIC Study

This video discusses the relationship between proton pump inhibitors (PPIs) and dementia risk, based on the Atherosclerosis Risk in Communities Study. While short-term use may not elevate risk, long-term utilization…

Другая Кухня · Aug 8, 2024 2,490 views

Proton Pump Inhibitors and Dementia Risk: Key Insights from ARIC Study

This video delves into the Atherosclerosis Risk in Communities Study, analyzing the relationship between proton pump inhibitors (PPIs) and dementia risk. Findings indicate long-term PPI use may increase dementia risk…

Другая Кухня · Aug 12, 2024 2,396 views

recovery&renewal

@recover2renew · X

RT @recover2renew: @ProfRobHoward @Jeff_Browndyke @RenegadeSynapse https://t.co/IlRiwHVEsi